Literature DB >> 29580796

Effect of Levosimendan on Renal Outcome in Cardiac Surgery Patients With Chronic Kidney Disease and Perioperative Cardiovascular Dysfunction: A Substudy of a Multicenter Randomized Trial.

Alberto Zangrillo1, Gabriele Alvaro2, Alessandro Belletti3, Antonio Pisano4, Luca Brazzi5, Maria G Calabrò6, Fabio Guarracino7, Tiziana Bove6, Evgeny V Grigoryev8, Fabrizio Monaco6, Vladimir A Boboshko9, Valery V Likhvantsev10, Anna M Scandroglio6, Gianluca Paternoster11, Rosalba Lembo6, Samuele Frassoni6, Marco Comis12, Vadim V Pasyuga13, Paolo Navalesi14, Vladimir V Lomivorotov9.   

Abstract

OBJECTIVE: Acute kidney injury (AKI) occurs frequently after cardiac surgery. Levosimendan might reduce the incidence of AKI in patients undergoing cardiac surgery. The authors investigated whether levosimendan administration could reduce AKI incidence in a high-risk cardiac surgical population.
DESIGN: Post hoc analysis of a multicenter randomized trial.
SETTING: Cardiac surgery operating rooms and intensive care units of 14 centers in 3 countries. PARTICIPANTS: The study comprised 90 patients who underwent mitral valve surgery with an estimated glomerular filtration rate <60 mL/min/1.73 m2 and perioperative myocardial dysfunction.
INTERVENTIONS: Patients were assigned randomly to receive levosimendan (0.025-0.2 μg/kg/min) or placebo in addition to standard inotropic treatment.
MEASUREMENTS AND MAIN RESULTS: Forty-six patients were assigned to receive levosimendan and 44 to receive placebo. Postoperative AKI occurred in 14 (30%) patients in the levosimendan group versus 23 (52%) in the placebo group (absolute difference -21.8; 95% confidence interval -41.7 to -1.97; p = 0.035). The incidence of major complications also was lower (18 [39%]) in the levosimendan group versus that in the placebo group (29 [66%]) (absolute difference -26.8 [-46.7 to -6.90]; p = 0.011). A trend toward lower serum creatinine at intensive care unit discharge was observed in the levosimendan group (1.18 [0.99-1.49] mg/dL) versus that in the placebo group (1.39 [1.05-1.76] mg/dL) (95% confidence interval -0.23 [-0.49 to 0.01]; p = 0.07).
CONCLUSIONS: Levosimendan may improve renal outcome in cardiac surgery patients with chronic kidney disease undergoing mitral valve surgery who develop perioperative myocardial dysfunction. Results of this exploratory analysis should be investigated in future properly designed randomized controlled trials.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute kidney injury; cardiac surgery; chronic kidney disease; hemodynamic support; inotropes; levosimendan; low cardiac output syndrome; mitral valve surgery

Mesh:

Substances:

Year:  2018        PMID: 29580796     DOI: 10.1053/j.jvca.2018.02.039

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  8 in total

1.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.

Authors:  Wanyu Wang; Xiaoshuang Zhou; Xinyang Liao; Bin Liu; Hai Yu
Journal:  J Anesth       Date:  2019-04-25       Impact factor: 2.078

2.  Renal and Neurologic Benefit of Levosimendan vs Dobutamine in Patients With Low Cardiac Output Syndrome After Cardiac Surgery: Clinical Trial FIM-BGC-2014-01.

Authors:  Jose L Guerrero-Orriach; Alfredo Malo-Manso; Marta Ramirez-Aliaga; Ana Isabel Florez Vela; Manuel Galán-Ortega; Isabel Moreno-Cortes; Inmaculada Gonzalez-Almendros; Alicia Ramirez-Fernandez; Daniel Ariza-Villanueva; Juan Jose Escalona-Belmonte; Guillermo Quesada-Muñoz; Enrique Sepúlveda-Haro; Salvador Romero-Molina; Inmaculada Bellido-Estevez; Aurelio Gomez-Luque; Manuel Rubio-Navarro; Juan Alcaide-Torres; Concepcion Santiago-Fernandez; Lourdes Garrido-Sanchez; Jose Cruz-Mañas
Journal:  Front Pharmacol       Date:  2020-08-26       Impact factor: 5.810

Review 3.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2020-07       Impact factor: 3.105

Review 4.  Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  Card Fail Rev       Date:  2020-07-08

Review 5.  Valvular Heart Disease in Patients with Chronic Kidney Disease.

Authors:  Konstantina Kipourou; Jamie M O'Driscoll; Rajan Sharma
Journal:  Eur Cardiol       Date:  2022-01-31

6.  Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.

Authors:  Oliver K Jawitz; Amanda S Stebbins; Vignesh Raman; Brooke Alhanti; Sean van Diepen; Matthias Heringlake; Stephen Fremes; Richard Whitlock; Steven R Meyer; Rajendra H Mehta; Mark Stafford-Smith; Shaun G Goodman; John H Alexander; Renato D Lopes
Journal:  Am Heart J       Date:  2020-10-28       Impact factor: 4.749

Review 7.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

Authors:  Antoine Herpain; Stefaan Bouchez; Massimo Girardis; Fabio Guarracino; Johann Knotzer; Bruno Levy; Tobias Liebregts; Piero Pollesello; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Fabio Sangalli
Journal:  J Cardiovasc Pharmacol       Date:  2019-01       Impact factor: 3.105

8.  Prospective Study on the Postoperative Use of Levosimendan After Conventional Heart Valve Replacement.

Authors:  Wei Sheng; Hui Qiao; Zhaozhuo Niu; Tianyi Wang; Haoyou Li; Wenfeng Zhang; Jiantao Wu; Xiao Lv
Journal:  Med Sci Monit       Date:  2021-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.